Last Updated on October 15, 2024 by The Health Master
The United States Food and Drugs Administration (USFDA) has given tentative approval to Zydus Lifesciences to market Levomilnacipran extended-release capsules, 20 mg, 40 mg, 80 mg and 120 mg, according to a company statement.
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder (MDD) in adults.
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad, the statement said.
USFDA gives approval for Febuxostat tablets
USFDA gives approval for Prasugrel tablets
USFDA approves Fesoterodine Fumarate Extended-Release tablets
USFDA gives final approval for this Insomnia drug
USFDA approves this monoclonal antibody to treat multiple sclerosis
USFDA gives final approval to this breast cancer injection
IPC includes dissolution test in IP: Read details
NPPA fixes retail price of 12 formulations: January 2023
Drug recall: Epinephrine API recalled due to this reason
Deadline for Medical Colleges to submit PG Admissions info: NMC
NPPA revised Retail Price of 93 scheduled formulations: January 2023
Tramadol: 3 Pharmaceutical Companies under scanner
NABL suspends accreditation of 80 laboratories
List of approved FDCs (Fixed Dose Combinations) Updated
List of approved New Drugs Updated
Latest Notifications regarding Pharmaceutical
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
